The company's products include AMITIZA and RESCULA, and they have a late-stage pipeline of product candidates in clinical development for orphan disease areas. Sucampo focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. They are used for the treatment of chronic and idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation, helping adult patients to live better lives. Sucampo is a global company with headquarters in Rockville, Maryland, and operations in Japan, Switzerland, and the U.K.